Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) EBT Margin (2018 - 2025)

BioNexus Gene Lab's EBT Margin history spans 8 years, with the latest figure at 214.18% for Q4 2025.

  • Quarterly results put EBT Margin at 214.18% for Q4 2025, down 19746.0% from a year ago — trailing twelve months through Dec 2025 was 40.2% (down 2343.0% YoY), and the annual figure for FY2025 was 40.2%, down 2343.0%.
  • EBT Margin for Q4 2025 was 214.18% at BioNexus Gene Lab, down from 27.87% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 12.9% in Q2 2024 to a low of 214.18% in Q4 2025.
  • The 5-year median for EBT Margin is 4.0% (2024), against an average of 21.95%.
  • The sharpest move saw EBT Margin skyrocketed 4809bps in 2024, then tumbled -19746bps in 2025.
  • Year by year, EBT Margin stood at 6.07% in 2021, then tumbled by -174bps to 4.49% in 2022, then surged by 349bps to 11.16% in 2023, then plummeted by -250bps to 16.72% in 2024, then plummeted by -1181bps to 214.18% in 2025.
  • According to Business Quant data, EBT Margin over the past three periods came in at 214.18%, 27.87%, and 27.26% for Q4 2025, Q3 2025, and Q2 2025 respectively.